Trial Profile

A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac in Subjects With Mucinous Cystic Pancreatic Neoplasms

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Sponsors Nanology

Most Recent Events

20 Dec 2022 According to a NanOlogy media release, results from this study presented at Endoscopy International Open.
20 Dec 2022 Results published in the NanOlogy Media Release
09 Jun 2021 Interim results (n=5)evaluating safety, tolerability, pharmacokinetics, and cyst response in BD-IPMNs published in the NanOlogy Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com